WAVE Life Sciences Ltd. (NASDAQ:WVE) has been assigned a $34.00 target price by analysts at Mizuho in a research note issued to investors on Friday. The firm currently has a “buy” rating on the stock. Mizuho’s target price points to a potential upside of 103.59% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Jefferies Group LLC set a $42.00 price target on shares of WAVE Life Sciences and gave the company a “buy” rating in a report on Thursday, June 8th. JMP Securities reissued an “outperform” rating and issued a $40.00 price target on shares of WAVE Life Sciences in a report on Friday, June 9th. Zacks Investment Research cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine cut shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Two research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. WAVE Life Sciences has a consensus rating of “Hold” and a consensus price target of $40.00.

WAVE Life Sciences (NASDAQ:WVE) traded up 2.545% during mid-day trading on Friday, hitting $17.125. The stock had a trading volume of 79,516 shares. WAVE Life Sciences has a 1-year low of $15.15 and a 1-year high of $40.15. The company has a 50-day moving average price of $18.38 and a 200 day moving average price of $22.82. The company’s market cap is $475.39 million.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.14. The company had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.73 million. WAVE Life Sciences had a negative net margin of 3,375.12% and a negative return on equity of 55.19%. Equities research analysts forecast that WAVE Life Sciences will post ($3.79) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/18/wave-life-sciences-ltd-wve-pt-set-at-34-00-by-mizuho.html.

In other WAVE Life Sciences news, insider Michael A. Panzara sold 7,414 shares of the stock in a transaction that occurred on Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total transaction of $123,591.38. Following the transaction, the insider now owns 15,336 shares in the company, valued at approximately $255,651.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 53.00% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. American International Group Inc. raised its position in shares of WAVE Life Sciences by 7.1% in the first quarter. American International Group Inc. now owns 4,554 shares of the company’s stock worth $125,000 after buying an additional 302 shares during the last quarter. Nationwide Fund Advisors raised its position in shares of WAVE Life Sciences by 58.1% in the second quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock worth $125,000 after buying an additional 2,470 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of WAVE Life Sciences by 71.0% in the second quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after buying an additional 3,912 shares during the last quarter. EcoR1 Capital LLC acquired a new position in shares of WAVE Life Sciences during the first quarter worth about $275,000. Finally, Vident Investment Advisory LLC acquired a new position in shares of WAVE Life Sciences during the first quarter worth about $293,000. Hedge funds and other institutional investors own 57.03% of the company’s stock.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Analyst Recommendations for WAVE Life Sciences (NASDAQ:WVE)

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.